Risk of hematological, gastrointestinal, and hepatic toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e16553-e16553
Author(s):  
Henry Palangdao Igid ◽  
Kyaw Zin Thein ◽  
Sriman Swarup ◽  
Anita Sultan ◽  
Fred L. Hardwicke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Randomized Controlled Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Meta Analysis ◽  
Advanced Renal Cell Carcinoma ◽  
Controlled Trials ◽  
Phase 3 ◽  
Randomized Controlled

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

2019 ◽  
Author(s):  
Brian Rini ◽  
Sumanta K. Pal ◽  
Bernard J. Escudier ◽  
Michael B. Atkins ◽  
Thomas E. Hutson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document